See more : China Western Power Industrial Co., Ltd. (002630.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Ensysce Biosciences, Inc. (ENSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ensysce Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pranda Jewelry Public Company Limited (PDJ.BK) Income Statement Analysis – Financial Results
- Goodricke Group Limited (GOODRICKE.BO) Income Statement Analysis – Financial Results
- CT Real Estate Investment Trust (CRT-UN.TO) Income Statement Analysis – Financial Results
- Mikron Holding AG (0QQF.L) Income Statement Analysis – Financial Results
- E-data Corporation (EDTA) Income Statement Analysis – Financial Results
Ensysce Biosciences, Inc. (ENSC)
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.23M | 2.52M | 3.53M | 3.93M | 1.76M | 0.00 | 0.00 |
| Cost of Revenue | 7.59M | 19.84M | 151.00 | 1.37M | 3.33M | 1.56M | 0.00 |
| Gross Profit | -5.36M | -17.31M | 3.53M | 2.56M | -1.56M | -1.56M | 0.00 |
| Gross Profit Ratio | -240.17% | -686.08% | 100.00% | 65.18% | -88.70% | 0.00% | 0.00% |
| Research & Development | 7.59M | 19.84M | 4.69M | 4.39M | 3.40M | 0.00 | 0.00 |
| General & Administrative | 5.36M | 6.91M | 18.71M | 1.15M | 6.93M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -3.60M | 0.00 | 0.00 |
| SG&A | 5.36M | 6.91M | 18.71M | 1.15M | 3.33M | 1.56M | 146.70K |
| Other Expenses | -7.59M | -2.52M | -3.53M | -3.93M | 0.00 | 600.00K | 0.00 |
| Operating Expenses | 5.36M | 24.22M | 19.87M | 1.61M | 3.33M | 959.25K | 146.70K |
| Cost & Expenses | 12.95M | 24.22M | 19.87M | 1.61M | 3.33M | 959.24K | 146.70K |
| Interest Income | 0.00 | 1.25M | 3.22M | 719.65K | 4.25M | 3.63M | 0.00 |
| Interest Expense | 353.95K | 109.53K | 1.30M | 995.50K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 151.00 | 151.00 | 201.00 | 201.00 | 161.14K | 0.00 |
| EBITDA | -10.72M | -24.22M | -19.87M | -1.61M | 921.15K | 2.68M | -27.56K |
| EBITDA Ratio | -480.52% | -959.91% | -562.71% | -41.03% | -188.70% | 0.00% | 0.00% |
| Operating Income | -10.72M | -24.22M | -19.87M | -1.61M | -3.33M | -959.24K | -146.70K |
| Operating Income Ratio | -480.52% | -959.91% | -562.71% | -41.04% | -188.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 91.91K | 14.41K | -9.28M | 1.45M | 4.25M | 3.64M | 119.14K |
| Income Before Tax | -10.63M | -24.21M | -29.15M | -160.88K | 921.15K | 2.68M | -27.56K |
| Income Before Tax Ratio | -476.40% | -959.33% | -825.38% | -4.09% | 52.22% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 753.88K | -151.00 | 777.85K | -555.20K | 553.92K | 3.64K |
| Net Income | -10.61M | -24.96M | -29.15M | -938.73K | 1.48M | -1.34M | -31.19K |
| Net Income Ratio | -475.81% | -989.21% | -825.38% | -23.88% | 83.70% | 0.00% | 0.00% |
| EPS | -4.69 | -138.73 | -346.90 | -14.29 | 15.02 | -12.91 | -0.30 |
| EPS Diluted | -4.69 | -138.73 | -346.90 | -13.65 | 15.02 | -12.91 | -0.30 |
| Weighted Avg Shares Out | 2.26M | 179.93K | 84.02K | 65.70K | 98.26K | 104.02K | 105.00K |
| Weighted Avg Shares Out (Dil) | 2.26M | 179.93K | 84.02K | 68.78K | 98.26K | 104.02K | 105.00K |
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
Ensysce Biosciences Receives Notice from Nasdaq
Ensysce Biosciences Presenting at Upcoming Meetings
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
Source: https://incomestatements.info
Category: Stock Reports